Stay Informed

Get email alerts when new recalls match your interests.

Recall data is updated hourly from official government sources. Very recent recalls may not yet appear. About our data sources

About

We make U.S. recall data searchable and accessible for consumers and businesses.

Site

FAQ
Browse by State
Statistics
Recall Classifications
About
Enterprise API

Legal

Privacy Policy
Terms of Service
Report Incorrect Info

Official Sources

FDA Recalls ↗
USDA FSIS ↗
CPSC Recalls ↗
NHTSA Recalls ↗

RSS Feed

Home
/
Medication

Medication Recalls

Browse drug and medication recalls including prescription drugs, OTC medications, and supplements. Stay informed about pharmaceutical safety alerts.

Get alerts for medication RSS feed

Showing 901–920 of 1639 recalls

Filter by date, severity, state →

Clobetasol Propionate Ointment (Akorn) – Stability Study Halt (2023)

CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Class IIModerate

FDAApr 26, 2023Nationwide• Akorn, Inc.

Olopatadine HCl Ophthalmic Solution (Akorn) – Stability Studies Discontinued (2023)

CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Class IIModerate

FDAApr 26, 2023Nationwide• Akorn, Inc.

Vitamin D Supplement Drops (Akorn) – Stability Studies Discontinued (2023)

CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Class IIModerate

FDAApr 26, 2023Nationwide• Akorn, Inc.

Cromolyn Sodium Ophthalmic Solution (Akorn) – Stability Study Halt (2023)

CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Class IIModerate

FDAApr 26, 2023Nationwide• Akorn, Inc.

Acyclovir Oral Suspension (Akorn) – Stability Studies Discontinued (2023)

CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Class IIModerate

FDAApr 26, 2023Nationwide• Akorn, Inc.

Pro Power Knight Plus Capsule (Gadget Island) – Undeclared Drug Ingredients (2023)

Undeclared Allergen

Marketed without an Approved NDA/ANDA: FDA analysis found product to be tainted with undeclared sildenafil and tadalafil, ingredients found in FDA approved products for the treatment of male sexual enhancement, making this an unapproved drug.

Class IHigh

FDAApr 26, 2023Nationwide• Gadget Island, Inc

Lidocaine HCl Jelly (Akorn) – Stability Studies Discontinued (2023)

CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Class IIModerate

FDAApr 26, 2023Nationwide• Akorn, Inc.

Lorazepam Oral Concentrate (Akorn) – Stability Studies Discontinued (2023)

CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Class IIModerate

FDAApr 26, 2023Nationwide• Akorn, Inc.

Valproic Acid Oral Solution (Akorn) – Stability Studies Discontinued (2023)

CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Class IIModerate

FDAApr 26, 2023Nationwide• Akorn, Inc.

Acetaminophen & Codeine Oral Solution (Akorn) – Stability Studies Discontinued (2023)

CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Class IIModerate

FDAApr 26, 2023Nationwide• Akorn, Inc.

Tobramycin Ophthalmic Solution (Akorn) – Stability Studies Discontinued (2023)

CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Class IIModerate

FDAApr 26, 2023Nationwide• Akorn, Inc.

Calcitriol Injection (Akorn) – Stability Studies Discontinued (2023)

CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Class IIModerate

FDAApr 26, 2023Nationwide• Akorn, Inc.

Lactulose Solution (Akorn) – Stability Studies Discontinued (2023)

CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Class IIModerate

FDAApr 26, 2023Nationwide• Akorn, Inc.

Acetic Acid Otic Solution (Akorn) – Stability Studies Discontinued (2023)

CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Class IIModerate

FDAApr 26, 2023Nationwide• Akorn, Inc.

Ephedrine Sulfate Injection 50mg/mL (Akorn) – Business Closure Stability Issue (2023)

CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Class IIModerate

FDAApr 26, 2023Nationwide• Akorn, Inc.

Apraclonidine Ophthalmic Solution (Akorn) – Stability Studies Discontinued (2023)

CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Class IIModerate

FDAApr 26, 2023Nationwide• Akorn, Inc.

NUX Male Enhancement Capsule (Gadget Island) – Undeclared Ingredients (2023)

Undeclared Allergen

Class IHigh

FDAApr 26, 2023Nationwide• Gadget Island, Inc

Sodium Chloride Ophthalmic Ointment 5% (Akorn) – Business Closure Stability Issue (2023)

CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Class IIModerate

FDAApr 26, 2023Nationwide• Akorn, Inc.

Dynamite Super Capsule (Gadget Island) – Undeclared Drug Ingredients (2023)

Undeclared Allergen

Class IHigh

FDAApr 26, 2023Nationwide• Gadget Island, Inc

Fentanyl Citrate Injection 100mcg (Akorn) – Business Closure Stability Issue (2023)

CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Class IIModerate

FDAApr 26, 2023Nationwide• Akorn, Inc.

1...44 454647 48...82

Page 46 of 82Next

Browse Other Categories

Food Baby Products Pet Products Toys Electronics Household Vehicles Medical Devices Other